Yang Watkin Phoebe L. 4

What Happened

• Phoebe L. Yang (listed in the filing as Yang Watkin Phoebe L.), a director of GE HealthCare Technologies Inc. (GEHC), received an award of 3,586 restricted stock units (RSUs) on May 7, 2026 (acquisition price $0.00) and made an open‑market purchase of 1,000 shares on May 8, 2026 at a weighted average price of $63.01 for a total cash outlay of $63,006. The award is a grant of RSUs (not an immediate cash payment).

Key Details

• Transactions: RSU award of 3,586 RSUs on 2026-05-07 (price reported $0.00); open‑market purchase of 1,000 shares on 2026-05-08 at a weighted avg. $63.01 ($62.97–$63.01 range).
• Total cash spent on purchase: $63,006.
• Shares owned after the transactions: not specified in the provided filing details.
• Footnotes: F1 — 100% of the RSUs vest on the earlier of GE HealthCare’s next annual meeting or May 7, 2027; settlement of vested RSUs may be deferred under the director deferral plan. F2 — each RSU equals one share at settlement. F3 — purchase price is a weighted average; purchases occurred at prices between $62.97 and $63.01.
• Filing/timeliness: Form 4 was filed on 2026-05-11 for transactions on 2026-05-07 and 2026-05-08; the filing appears timely.

Context

• RSUs are a compensation award that convert to shares at settlement (subject to vesting and any deferral election). The open‑market purchase is a straightforward buy (cash purchase); purchases by insiders can be interpreted as the insider acquiring equity but do not by themselves prove intent or future performance.